Browse by Poster Presenter

Skip to main content

ASCPT 2023 Annual Meeting Main banner

Tweets by ASCPT 2023 Annual Meeting

Browse by Poster Presenter

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

S
Salah, Lana

University of Colorado Anschutz Medical Campus
PII-021 - QUANTIFYING THE EFFECTS OF ALCOHOL USE ON DRIED BLOOD SPOT CONCENTRATIONS OF SOFOSBUVIR’S ACTIVE METABOLITE, 007-TP, IN PERSONS WITH HEPATITIS C USING PHOSPHATIDYLETHANOL AS AN OBJECTIVE BIOMARKER OF ALCOHOL CONSUMPTION.
Lana Salah
Favorite
Salem, Ahmed

University of Maryland Baltimore
PT-016 - POPULATION PHARMACOKINETIC MODELING TO GUIDE THE OPTIMAL DOSING FOR UNFRACTIONATED HEPARIN IN PEDIATRICS REQUIRING EXTRACORPOREAL MEMBRANE OXYGENATION.
Ahmed Salem
Favorite
Salem, Farzaneh

GlaxoSmithKline
PII-116 - PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING FOR DEVELOPMENT AND APPLICATIONS OF A VIRTUAL CELIAC DISEASE POPULATION USING FELODIPINE AS A MODEL DRUG.
Farzaneh Salem
Favorite
PWI-004 - PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING FOR DEVELOPMENT AND APPLICATIONS OF A VIRTUAL CELIAC DISEASE POPULATION USING FELODIPINE AS A MODEL DRUG.
Farzaneh Salem
Favorite
Salguero B, Maria

The University of Chicago
PII-119 - THE IMPACT OF PARENT-OF-ORIGIN ON CHILDHOOD GROWTH TRAJECTORIES AND SULFONYLUREAS USE IN CHILDREN WITH HNF1A-MODY IN THE U.S. MONOGENIC DIABETES REGISTRY.
Maria Salguero B
Favorite
RWE-011 - THE IMPACT OF PARENT-OF-ORIGIN ON CHILDHOOD GROWTH TRAJECTORIES AND SULFONYLUREAS USE IN CHILDREN WITH HNF1A-MODY IN THE U.S. MONOGENIC DIABETES REGISTRY.
Maria Salguero B
Favorite
Salimgareeva, Diana

Bashkir State Medical University
EP-022 - SELECTION OF COMPARISON DRUGS FOR ASSESSING THE CARDIAC PROTECTIVE PROPERTIES OF DRUG CANDIDATES.
Diana Salimgareeva
Favorite
Sano, Yamato

Pfizer R&D Japan
PI-039 - APPLICATION OF POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC MODELING TO SUPPORT DOSAGE REGIMEN OF FESOTERODINE IN PEDIATRICS WITH NEUROLOGICAL DETRUSOR OVERACTIVITY.
Yamato Sano
Favorite
Sathe, Abhishek

Gilead Sciences
PII-082 - POPULATION PHARMACOKINETICS (POPPK) OF SACITUZUMAB GOVITECAN (SG) IN PATIENTS (PTS) WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER (MBC) OR OTHER SOLID TUMORS.
Abhishek Sathe
Favorite
Schaller, Stephan

esqLABS GmbH
PI-080 - LEVERAGING PBPK-BASED ANALYSIS TO SUPPORT AN ADAPTIVE TRIAL DESIGN IN CHILDREN.
Stephan Schaller
Favorite
Schmith, Virginia (Ginny)

Schmith PK/PD Consulting LLC
PII-088 - THE EFFECT OF UGT INHIBITION ON THE PHARMACOKINETICS OF ECOPIPAM AND ITS METABOLITES.
Virginia (Ginny) Schmith
Favorite
Scholz, Erin

GlaxoSmithKline
PI-074 - A PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL EVALUATING THE DRUG-DRUG INTERACTION (DDI) POTENTIAL BETWEEN LAMOTRIGINE (LMT) AND ACETAMINOPHEN (APAP).
Erin Scholz
Favorite
Seo, Byeongjun

Cipherome, Inc
PI-022 - ANALYSIS OF TICAGRELOR AND PRASUGREL CORRELATION WITH CYP2C19 GENETIC VARIANTS AS ALTERNATIVE DRUGS FOR CLOPIDOGREL.
Byeongjun Seo
Favorite
Shabnaz, Samia

University of Florida
PII-052 - PROTEOMIC ANALYSIS OF CARFILZOMIB (CFZ) RELATED HEART FAILURE IN MULTIPLE MYELOMA (MM) PATIENTS FROM PROSPECTIVE STUDY OF CARDIAC EVENTS DURING PROTEASOME INHIBITOR THERAPY (PROTECT) STUDY.
Samia Shabnaz
Favorite
Shahin, Mohamed

Pfizer Global Research and Development
PI-047 - COMPARISON OF PATIENT-CENTRIC MICROSAMPLING VS. TRADITIONAL BLOOD SAMPLING FOR PHARMACOKINETIC ANALYSIS OF ABROCITINIB.
Mohamed Shahin
Favorite
Shahraz, Azar

AstraZeneca
PI-033 - A MECHANISTIC PK/PD MODEL OF AZD0171 (ANTI-LIF) TO SUPPORT PHASE 2 DOSE SELECTION.
Azar Shahraz
Favorite
PII-055 - INVESTIGATING THE EFFECT OF INFORMATIVE CENSORING ON THE KAPLAN-MEIER ESTIMATE OF ENDPOINTS IN ONCOLOGY CLINICAL TRIALS.
Azar Shahraz
Favorite
Shah, Shruti

GlaxoSmithKline
PII-124 - APPLICATION OF MACHINE LEARNING (ML) ON QSP VIRTUAL PATIENT POPULATION (VPOP) FOR IDENTIFICATION OF BIOMARKERS OF RESPONSE AND FOR SELECTION OF PRE-CONDITIONING REGIMEN FOR ENGINEERED T-CELL (ET-CELL) THERAPY.
Shruti Shah
Favorite
PWII-005 - APPLICATION OF MACHINE LEARNING (ML) ON QSP VIRTUAL PATIENT POPULATION (VPOP) FOR IDENTIFICATION OF BIOMARKERS OF RESPONSE AND FOR SELECTION OF PRE-CONDITIONING REGIMEN FOR ENGINEERED T-CELL (ET-CELL) THERAPY.
Shruti Shah
Favorite
Shakhnovich, Valentina

University of Missouri-Kansas City
PII-112 - MAGNETIC RESONANCE IMAGE-BASED ESTIMATES OF HEPATIC BLOOD FLOW IN CHILDREN WITH AND WITHOUT OBESITY; IMPLICATIONS FOR PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELS.
Valentina Shakhnovich
Favorite
PWI-003 - MAGNETIC RESONANCE IMAGE-BASED ESTIMATES OF HEPATIC BLOOD FLOW IN CHILDREN WITH AND WITHOUT OBESITY; IMPLICATIONS FOR PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELS.
Valentina Shakhnovich
Favorite
Sharma, Jyoti

Sanofi
PII-098 - PBPK MODELING TO ASSESS DRUG-DRUG INTERACTION POTENTIAL OF VENGLUSTAT WITH CYP3A INHIBITORS.
Jyoti Sharma
Favorite
Shaul, Chanan

Shaary-Zedek Medical Center, Hadassha Medical Center
PII-086 - QUANTITATIVE EFFECT OF CYP2C9 INDUCTION BY DICLOXACILLIN ON THE NARROW THERAPEUTIC DRUGS: PHENYTOIN AND WARFARIN.
Chanan Shaul
Favorite
Shi, Alan

University of Southern California
PI-081 - ELEXACAFTOR/TEZACAFTOR/IVACAFTOR (ETI) -INDUCED REACTIVE OXYGEN SPECIES (ROS) PRODUCTION IN HEPG2 CELLS: A POTENTIAL MECHANISM OF DRUG-INDUCED LIVER INJURY (DILI)
Alan Shi
Favorite
Shi, Jian

Bristol Myers Squibb
PI-041 - BENEFIT-RISK OF FLAT-DOSING OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN THORACIC CANCER IMMUNOTHERAPY (1L METASTATIC NON-SMALL-CELL LUNG CANCER AND 1L UNRESECTABLE MALIGNANT PLEURAL MESOTHELIOMA).
Jian Shi
Favorite
Shimamoto, Yuko

Osaka University, National Cerebral and Cardiovascular
EP-017 - MODEL-INFORMED VANCOMYCIN DOSING TO ADDRESS DELAYED RENAL MATURATION IN INFANTS AND YOUNG CHILDREN WITH CONGENITAL HEART DISEASE.
Yuko Shimamoto
Favorite
Simental, Paul

University of California, San Diego
PI-103 - EVALUATING THE CONSISTENCY AND EXTENT OF IMMUNOGENICITY REPORTING FOR RECENTLY APPROVED BIOLOGICS.
Paul Simental
Favorite
Simeon, Segolene

University of California, San Francisco
PT-022 - OPTIMIZING LUMEFANTRINE DOSING IN YOUNG CHILDREN USING REAL WORLD DATA AND PHARMACOKINETIC/PHARMACODYNAMIC SIMULATIONS.
Segolene Simeon
Favorite
RWE-006 - OPTIMIZING LUMEFANTRINE DOSING IN YOUNG CHILDREN USING REAL WORLD DATA AND PHARMACOKINETIC/PHARMACODYNAMIC SIMULATIONS.
Segolene Simeon
Favorite
Singh, Aman

Takeda Development Center Americas, Inc.
PII-003 - INTEGRATED CELLULAR KINETIC (CK) – PHARMACODYNAMIC (PD) ANALYSIS FOR FIRST IN HUMAN DOSE-ESCALATION STUDY OF TAK-102: A GPC3 TARGETED AUTOLOGOUS CAR-T CELLS ARMORED WITH IL-7 AND CCL19.
Aman Singh
Favorite
Somani, Roopali

Nizam's Institute of Medical Sciences
EP-004 - A SINGLE CENTRE, PROSPECTIVE STUDY TO EVALUATE THE EFFECT OF DOUBLE CARBAPENEM BASED COLISTIN THERAPY VERSUS BEST AVAILABLE THERAPY FOR THE TREATMENT OF CARBAPENEM RESISTANT ENTEROBACTERIACEAE AT A TERTIARY CARE HOSPITAL IN INDIA.
Roopali Somani
Favorite
Song, Yang

Horizon Therapeutics
PII-071 - PHARMACOKINETICS (PK) OF HZN-825, A SMALL MOLECULE SELECTIVE ANTAGONIST OF LPAR1, AND THE EFFECT OF FOOD IN HEALTHY ADULT SUBJECTS.
Yang Song
Favorite
Sorour, Mohammed

Temple University
PII-102 - PREDICTION OF DRUG-DRUG INTERACTIONS (DDI) WITH A MODERATE CYP3A INDUCER: DEVELOPMENT AND VALIDATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL OF RIFABUTIN.
Mohammed Sorour
Favorite
Srinivas, Nithya

Sage Therapeutics, Inc.
PII-093 - ZURANOLONE, A NOVEL GABAA POSITIVE ALLOSTERIC MODULATOR, DOES NOT PROLONG THE QT INTERVAL.
Nithya Srinivas
Favorite
Stancil, Stephani

Children's Mercy Kansas City
PII-006 - EARLY PHARMACODYNAMIC BIOMARKER DEVELOPMENT IN ADOLESCENTS WITH EATING DISORDERS.
Stephani Stancil
Favorite
Staples, Jack

University of Montana
PI-021 - A RETROSPECTIVE GENOME-WIDE ASSOCIATION STUDY OF ANTIPSYCHOTIC DRUG RESPONSE IN PEDIATRIC PATIENTS WITH PSYCHIATRIC ILLNESS IN A RURAL HEALTHCARE SETTING.
Jack Staples
Favorite
Stevenson, James

Johns Hopkins University
PI-025 - DOCUMENTATION OF RESULTS AND MEDICATION PRESCRIBING AFTER COMBINATORIAL PSYCHIATRIC PHARMACOGENETIC TESTING.
James Stevenson
Favorite
Stitt, Gideon

Children's Hospital of Philadelphia
PII-077 - POPULATION PHARMACOKINETIC MODELING AND SIMULATION OF TRANEXAMIC ACID IN ADULTS TRAUMA PATIENTS.
Gideon Stitt
Favorite
Strotmann, Rainer

Merck KGaA
PII-058 - LOW SENSITIVITY OF TEPOTINIB TO DRUG-DRUG INTERACTIONS WITH CYP3A4 AND P-GP MODULATORS.
Rainer Strotmann
Favorite
Su, Mei-Chi

Takeda Development Center Americas Inc.
PII-002 - DEVELOPMENT OF A MULTISCALE MECHNISM-BASED CELLULAR KINETIC-PHARMACODYNAMIC (CK-PD) MODEL FOR DUAL-TARGETED BICISTRONIC CAR-T CELL THERAPY.
Mei-Chi Su
Favorite